vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and KILROY REALTY CORP (KRC). Click either name above to swap in a different company.
KILROY REALTY CORP is the larger business by last-quarter revenue ($272.2M vs $183.1M, roughly 1.5× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 6.3%, a 7.1% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -5.0%). KILROY REALTY CORP produced more free cash flow last quarter ($450.3M vs $24.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -1.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Kilroy Realty Corp is a leading U.S. real estate investment trust that develops, owns, and operates premium office, life science, and mixed-use properties primarily across high-growth West Coast markets including Los Angeles, San Francisco, Seattle, and San Diego. It serves tenants across the technology, life sciences, media, and creative sectors, with a core focus on delivering sustainable, future-ready workspaces tailored to modern business needs.
AMPH vs KRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $272.2M |
| Net Profit | $24.4M | $17.1M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | — |
| Net Margin | 13.3% | 6.3% |
| Revenue YoY | -1.8% | -5.0% |
| Net Profit YoY | -35.7% | -73.7% |
| EPS (diluted) | $0.51 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $272.2M | ||
| Q3 25 | $191.8M | $279.7M | ||
| Q2 25 | $174.4M | $289.9M | ||
| Q1 25 | $170.5M | $270.8M | ||
| Q4 24 | $186.5M | $286.4M | ||
| Q3 24 | $191.2M | $289.9M | ||
| Q2 24 | $182.4M | $280.7M | ||
| Q1 24 | $171.8M | $278.6M |
| Q4 25 | $24.4M | $17.1M | ||
| Q3 25 | $17.4M | $162.3M | ||
| Q2 25 | $31.0M | $79.6M | ||
| Q1 25 | $25.3M | $43.7M | ||
| Q4 24 | $38.0M | $65.0M | ||
| Q3 24 | $40.4M | $57.7M | ||
| Q2 24 | $37.9M | $54.5M | ||
| Q1 24 | $43.2M | $55.7M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | — | ||
| Q2 25 | 24.2% | — | ||
| Q1 25 | 21.9% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 29.8% | — | ||
| Q2 24 | 30.3% | — | ||
| Q1 24 | 27.9% | — |
| Q4 25 | 13.3% | 6.3% | ||
| Q3 25 | 9.0% | 58.0% | ||
| Q2 25 | 17.8% | 27.4% | ||
| Q1 25 | 14.8% | 16.1% | ||
| Q4 24 | 20.4% | 22.7% | ||
| Q3 24 | 21.1% | 19.9% | ||
| Q2 24 | 20.8% | 19.4% | ||
| Q1 24 | 25.1% | 20.0% |
| Q4 25 | $0.51 | $0.11 | ||
| Q3 25 | $0.37 | $1.31 | ||
| Q2 25 | $0.64 | $0.57 | ||
| Q1 25 | $0.51 | $0.33 | ||
| Q4 24 | $0.74 | $0.50 | ||
| Q3 24 | $0.78 | $0.44 | ||
| Q2 24 | $0.73 | $0.41 | ||
| Q1 24 | $0.81 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $179.3M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $5.4B |
| Total Assets | $1.6B | $10.9B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $179.3M | ||
| Q3 25 | $276.2M | $372.4M | ||
| Q2 25 | $231.8M | $193.1M | ||
| Q1 25 | $236.9M | $146.7M | ||
| Q4 24 | $221.6M | $165.7M | ||
| Q3 24 | $250.5M | $625.4M | ||
| Q2 24 | $217.8M | $835.9M | ||
| Q1 24 | $289.6M | $855.0M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $5.4B | ||
| Q3 25 | $776.7M | $5.5B | ||
| Q2 25 | $757.5M | $5.4B | ||
| Q1 25 | $751.3M | $5.4B | ||
| Q4 24 | $732.3M | $5.4B | ||
| Q3 24 | $727.7M | $5.4B | ||
| Q2 24 | $713.3M | $5.4B | ||
| Q1 24 | $672.4M | $5.4B |
| Q4 25 | $1.6B | $10.9B | ||
| Q3 25 | $1.7B | $11.0B | ||
| Q2 25 | $1.6B | $10.9B | ||
| Q1 25 | $1.6B | $10.9B | ||
| Q4 24 | $1.6B | $10.9B | ||
| Q3 24 | $1.5B | $11.4B | ||
| Q2 24 | $1.5B | $11.5B | ||
| Q1 24 | $1.6B | $11.6B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $566.3M |
| Free Cash FlowOCF − Capex | $24.6M | $450.3M |
| FCF MarginFCF / Revenue | 13.4% | 165.4% |
| Capex IntensityCapex / Revenue | 4.5% | 42.6% |
| Cash ConversionOCF / Net Profit | 1.35× | 33.10× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $833.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $566.3M | ||
| Q3 25 | $52.6M | $176.6M | ||
| Q2 25 | $35.6M | $143.7M | ||
| Q1 25 | $35.1M | $136.9M | ||
| Q4 24 | $29.0M | $541.1M | ||
| Q3 24 | $60.0M | $176.3M | ||
| Q2 24 | $69.1M | $88.7M | ||
| Q1 24 | $55.3M | $167.9M |
| Q4 25 | $24.6M | $450.3M | ||
| Q3 25 | $47.2M | $148.7M | ||
| Q2 25 | $25.0M | $118.4M | ||
| Q1 25 | $24.4M | $115.6M | ||
| Q4 24 | $16.6M | $440.8M | ||
| Q3 24 | $46.2M | $147.2M | ||
| Q2 24 | $63.1M | $69.5M | ||
| Q1 24 | $46.5M | $151.9M |
| Q4 25 | 13.4% | 165.4% | ||
| Q3 25 | 24.6% | 53.1% | ||
| Q2 25 | 14.3% | 40.9% | ||
| Q1 25 | 14.3% | 42.7% | ||
| Q4 24 | 8.9% | 153.9% | ||
| Q3 24 | 24.1% | 50.8% | ||
| Q2 24 | 34.6% | 24.7% | ||
| Q1 24 | 27.1% | 54.5% |
| Q4 25 | 4.5% | 42.6% | ||
| Q3 25 | 2.8% | 10.0% | ||
| Q2 25 | 6.1% | 8.7% | ||
| Q1 25 | 6.3% | 7.9% | ||
| Q4 24 | 6.7% | 35.0% | ||
| Q3 24 | 7.2% | 10.1% | ||
| Q2 24 | 3.3% | 6.8% | ||
| Q1 24 | 5.1% | 5.7% |
| Q4 25 | 1.35× | 33.10× | ||
| Q3 25 | 3.03× | 1.09× | ||
| Q2 25 | 1.15× | 1.81× | ||
| Q1 25 | 1.39× | 3.13× | ||
| Q4 24 | 0.76× | 8.32× | ||
| Q3 24 | 1.48× | 3.06× | ||
| Q2 24 | 1.82× | 1.63× | ||
| Q1 24 | 1.28× | 3.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
KRC
Segment breakdown not available.
